A Study of ATR-101 for the Treatment of Endogenous Cushing's Syndrome
Status:
Terminated
Trial end date:
2019-08-12
Target enrollment:
Participant gender:
Summary
This is a Phase 2 multicenter, randomized, double-blind, placebo controlled study of ATR-101
to evaluate the efficacy and safety of orally-administered ATR-101 in adults with endogenous
Cushing's syndrome. Following wash-out (if needed), all eligible subjects will enter an
open-label intra-subject dose-escalation period of 8 weeks' duration, followed either by a
double-blind randomized withdrawal period of 4 weeks' duration (if the subject meets
randomization criteria) or by an additional open label dosing period of 4 weeks' duration (if
the subject does not meet randomization criteria).It is anticipated that the overall duration
of the study per subject will range from approximately 16-22 weeks.
Phase:
Phase 2
Details
Lead Sponsor:
Millendo Therapeutics US, Inc. Millendo Therapeutics, Inc.